Identification of a mesenchymal-related signature associated with clinical prognosis in glioma

Abstract

Malignant glioma with a mesenchymal (MES) signature is characterized by shorter survival time due to aggressive dissemination and resistance to chemoradiotherapy. Here, this study used the TCGA database as the training set and the CGGA database as the testing set. Consensus clustering was performed on the two data sets, and it was found that two groups had distinguished prognostic and molecular features. Cox analysis and Lasso regression analysis were used to construct MES signature-based risk score model of glioma. Our results show that MES signature-based risk score model can be used to assess the prognosis of glioma. Three methods (ROC curve analyses, univariate Cox regression analysis, multivariate Cox regression analysis) were used to investigate the prognostic role of texture parameters. The result showed that the MES-related gene signature was proved to be an independent prognostic factor for glioma. Furthermore, functional analysis of the gene related to the risk signature showed that the genes sets were closely related to the malignant process of tumors. Finally, FCGR2A and EHD2 were selected for functional verification. Silencing these two genes inhibited the proliferation, migration and invasion of gliomas and reduced the expression of mesenchymal marker genes. Collectively, MES-related risk signature seems to provide a novel target for predicting the prognosis and treatment of glioma.

Comprehensive transcriptomic characterization reveals core genes and module associated with immunological changes via 1619 samples of brain glioma

“…1G and Supplementary Fig. S4 ), which is consistent with previous reports that these genes can overenhance or attenuate tumor growth [ 27 – 31 ].…”

“…FCGR2A is a cell surface receptor on phagocytic cells, involved in the process of phagocytosis and clearance of immune complexes [ 40 ]. Silencing FCGR2A expression suppressed glioma proliferation, migration and invasion [ 31 ]. Collectively, the function of these genes in tumors, especially VAMP8 and FCGR2A in gliomas, has been fully demonstrated.…”

Identification of an endoplasmic reticulum stress-related signature associated with clinical prognosis and immune therapy in glioma

“…In addition, integrating multiple gene biomarkers into a single signature was adopted because the prediction accuracy of the signature can be enhanced compared to a single biomarker [ 48 ]. Previous studies have reported that this biomarker signature of gliomas, such as the autophagy-related signature [ 49 , 50 ], ferroptosis-related signature [ 51 ], and mesenchymal-related signature [ 52 ], has shown strong prognostic power. In addition, although an ERS-related signature has been reported, it is entirely different from ours, and too many genes to make up the signature results inconvenient and impractical in clinical application.…”

Construction of Molecular Subtypes and Related Prognostic and Immune Response Models Based on M2 Macrophages in Glioblastoma

“…[49][50][51][52][53] FCGR2A, CYBB, CXCL8 and ITGB2 were significantly upregulated in GBM and associated with shorter overall survival of GBM patients. [54][55][56][57][58] As for the role of CCR1 in GBM, the results are still controversial. Zhang et al found that CCR1 and CCR5 were two key receptors of CCL8 and they triggered CCL8-induced invasion of GBM cells, 59 while Pham et al reported that individual deletion of CCR1 or CCR5 had little or no effect on the survival of tumor-bearing mice, or the number of GBM-infiltrated microglia/macrophages and lymphocytes.…”